The study and its comparison
Sixty symptomatic patients with frequent ventricular or supraventricular premature complexes were randomized to pidolate or placebo for 30 days. Rhythm frequency was assessed using 24-hour Holter monitoring. [1]
The active group had greater reductions in premature-complex frequency and symptom scores. The reported regimen provided 260 milligrams of elemental magnesium daily from 3 grams of the compound. [1]
What the finding establishes
These selected rhythm findings do not establish treatment for every cause of palpitations, atrial fibrillation or dangerous arrhythmia. They also cannot prove that another magnesium form gives the same result. Funding and conflicts were not established from the abstract. New rhythm symptoms require their own clinical assessment rather than identification by supplement response. [1]
A hypothetical distinction
Imagine two products have different magnesium salts. A trial of one does not directly test the other.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Successful improvement of frequency and symptoms of premature complexes after oral magnesium administration.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.